UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 15, 2018
Checkpoint Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-38128 |
|
47-2568632
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ | |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 15, 2018, the Board of Directors (the “Board”) of Checkpoint Therapeutics, Inc. (the “Company”) appointed both Christian Bechon and James. F. Oliviero to fill two new vacancies on the Board. Mr. Bechon and Mr. Oliviero will serve as directors until their terms expire at the 2019 annual meeting of stockholders, at which time they will stand for election by the Company’s stockholders. The Board announced Mr. Bechon’s appointment via press release on October 16, 2018. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is furnished as part of this report:
|
Exhibit |
Description | |
| 99.1 | Press Release of Checkpoint Therapeutics, Inc., dated October 16, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CHECKPOINT THERAPEUTICS, INC. | ||||
|
|
(Registrant) | ||||
|
Date: October 16, 2018
|
| ||||
| By: | /s/ James F. Oliviero | ||||
| Name: | James F. Oliviero | ||||
| Title: | President and Chief Executive Officer | ||||